Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Michael B Atkins,Opeyemi A Jegede,Naomi B Haas,David F Mcdermott,Mehmet A Bilen,Mark Stein,Jeffrey Sosman,Robert Alter,Elizabeth R Plimack,Moshe C Ornstein,Michael Hurwitz,David J Peace,David Einstein,Paul J Catalano,Hans Hammers,Meredith M Regan

doi:10.1136/jitc-2023-008293

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Michael B Atkins, Opeyemi A Jegede + Show 14 more

Open Access

PDF Available

https://doi.org/10.1136/jitc-2023-008293

Copy DOI

Export

Save

Cite

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Apr 1, 2024
Citations: 2	License type: CC BY-NC 4.0

Affiliation: Columbia University, The University of Texas Southwestern Medical Center

#Treatment-free Survival #International Metastatic RCC Database Consortium #Favorable-risk Patients #Start Of Subsequent Therapy #Treatment-related Adverse Events #Cessation Of Immunotherapy #Active Treatment Approach #Advanced Renal Cell Carcinoma #Favorable-risk Disease #Renal Cell Carcinoma

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

BackgroundAs part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy; both...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)